Get the Stockscreener App
0.87
1.14%
-0.01
Matinas Biopharma Holdings Inc stock is traded at $0.87, with a volume of 13,713.
It is down -1.14% in the last 24 hours and down -3.67% over the past month.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
See More
Previous Close:
$0.88
Open:
$0.85
24h Volume:
13,713
Relative Volume:
0.06
Market Cap:
$4.43M
Revenue:
-
Net Income/Loss:
$-21.13M
P/E Ratio:
-0.1816
EPS:
-4.79
Net Cash Flow:
$-16.95M
1W Performance:
-6.46%
1M Performance:
-3.67%
6M Performance:
+50.00%
1Y Performance:
+452.38%
1-Day Range:
$0.841
$0.87
1-Week Range:
$0.8168
$0.96
52-Week Range:
$0.09
$4.49
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Compare MTNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTNB
Matinas Biopharma Holdings Inc
|
0.87 | 4.48M | 0 | -21.13M | -16.95M | -4.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-26-20 | Resumed | Piper Sandler | Overweight |
| Jan-27-20 | Initiated | Piper Sandler | Overweight |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Jan-09-20 | Initiated | Aegis Capital | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
What is the risk reward ratio of investing in Matinas BioPharma Holdings Inc. stockSwing Trade Review With Proven Results - jammulinksnews.com
What institutional flow reveals about Matinas BioPharma Holdings Inc.Weekly Stock Market Strategy Summary - Newser
How to read the order book for Matinas BioPharma Holdings Inc.Swing Entry Risk Mitigation with Chart Analysis - Newser
Can Matinas BioPharma Holdings Inc. recover in the next quarterFree Technical Entry Strategy for Beginners - Newser
What the charts say about Clear Secure Inc. todayPredictive AI Signals for Short-Term Trading - Newser
Matinas BioPharma Holdings Inc. Stock Support and Resistance Levels You Should KnowFree Earnings Play Trade Plan With Alerts - Newser
What is the dividend policy of Matinas BioPharma Holdings Inc. stockExpert Picks Tips With High Returns - jammulinksnews.com
What institutional flow reveals about Matinas BioPharma Holdings IncRSI and MACD Signal Summary with Trends - Newser
What makes Matinas BioPharma Holdings Inc. stock price move sharplyShort Term Trading Opportunity Watch Sees Shift - metal.it
Why Matinas BioPharma Holdings Inc. stock attracts strong analyst attentionWeekly Movement Forecast With Chart Signals - Newser
Published on: 2025-07-28 19:10:29 - beatles.ru
How many analysts rate Matinas BioPharma Holdings Inc. as a “Buy”Free Wealth Planning Blueprint - jammulinksnews.com
When is Matinas BioPharma Holdings Inc. stock expected to show significant growthSuperior investment outcomes - jammulinksnews.com
What are the latest earnings results for Matinas BioPharma Holdings Inc.Invest smarter with actionable trading signals - jammulinksnews.com
How does Matinas BioPharma Holdings Inc. compare to its industry peersGet exclusive market analysis for investors - jammulinksnews.com
How does Matinas BioPharma Holdings Inc. generate profit in a changing economyAchieve breakthrough performance in the market - jammulinksnews.com
What are Matinas BioPharma Holdings Inc. company’s key revenue driversGet daily expert analysis on top stocks - jammulinksnews.com
What are analysts’ price targets for Matinas BioPharma Holdings Inc. in the next 12 monthsGrow your portfolio with growth-oriented stocks - jammulinksnews.com
Should I hold or sell Matinas BioPharma Holdings Inc. stock in 2025Invest confidently with professional advice - jammulinksnews.com
Published on: 2025-07-28 03:22:12 - jammulinksnews.com
Competitive Positioning of Matinas BioPharma Holdings Inc.: Is It Leading or LaggingDaily Swing Candidates - Newser
Matinas BioPharma Holdings Inc. Stock Performance After Earnings: Historical InsightsFree Stock Market Group - Newser
Is Matinas BioPharma Holdings Inc. a good long term investmentLightning-fast growth - PrintWeekIndia
What drives Matinas BioPharma Holdings Inc. stock priceMarket-beating returns - PrintWeekIndia
What analysts say about Matinas BioPharma Holdings Inc. stockExceptional market positioning - Autocar Professional
Matinas BioPharma Holdings Inc. Stock Analysis and ForecastOutstanding capital growth - PrintWeekIndia
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):